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Abstract 
β-Glucan is a polysaccharide that can be extracted from fungal cell walls. Wellmune WGP®, a preparation of β-1,3/1,6-
glucans, is a dietary supplement that has immunomodulating properties. Here we investigated the effect WGP had 
on a mouse model of asthma. OVA-induced asthma in mice is characterized by infiltration of eosinophils into the 
lung, production of Th2 cytokines and IgE. Daily oral administration of WGP (400 µg) significantly reduced the influx of 
eosinophils into the lungs of OVA-challenged mice compared to control mice. In addition, WGP inhibited pulmonary 
production of Th2 cytokines (IL-4, IL-5, IL-13), however serum IgE levels were unaffected by WGP treatment. These data 
indicate that WGP could potentially be useful as an oral supplement for some asthma patients, however, it would 
need to be combined with therapies that target other aspects of the disease such as IgE levels. As such, further stud-
ies that examine the potential of WGP in combination with other therapies should be explored.
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Background
Asthma is a chronic inflammatory airway disease that is 
caused by an allergic response in many cases. It affects 
5–10  % of the population and is associated with sig-
nificant morbidity and mortality (Barnes 2008). It is 
characterized by airway inflammation, airway hyper-
responsiveness (AHR) and mucus production (Holgate 
2012). Lung inflammation is caused by infiltration of 
eosinophils and T cells secreting Th2-cytokines (IL-4, 
IL-5, IL-13) into the lung. IL-4, IL-5 and IL-13 are impor-
tant for IgE production, eosinophil recruitment and sur-
vival, mucus secretion and AHR development (Lloyd and 
Hessel 2010). In addition to eosinophilic Th2-associated 
asthma, other asthma phenotypes occur such as neutro-
philic non-Th2 associated asthma. Currently the main 
treatment for asthma is corticosteroid administration, 
however some asthma phenotypes are refractory to cor-
ticosteroid therapy (Wenzel 2012). There is currently 
a significant level of research into the development of 
immunotherapies for asthma. These involve the targeting 
of IgE or cytokines such as IL-4, IL-5, IL-13. While many 
of these therapies are ineffective individually, research-
ers are currently examining the potential for combination 
therapies (Akdis 2012).
β-Glucan, a fungal cell wall extract, is marketed as a 
dietary supplement that can promote immune balance 
(Wichers 2009). β-Glucans are found in the cell walls of 
fungi, plants and some bacteria. β(1-3)- or β(1-6)-linked 
glucans are recognized by the Dectin-1 receptor. Dectin 
1 is a type II transmembrane C-type lectin-like receptor, 
which recognizes both soluble and particulate β-glucans 
(Brown 2006; Brown et  al. 2002, 2003). While Dectin-1 
can bind both soluble and particulate β-glucans, only 
particulate β-glucans activate Dectin-1 signaling and 
responses (Goodridge et  al. 2011). β-Glucan-induced 
signaling through Dectin-1 promotes Th1 and Th17 
responses (Leibundgut-Landmann et al. 2008).
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β-Glucan has been shown to exert beneficial therapeu-
tic effects against various diseases. It has been shown 
to stimulate tumoricidal activity when co-administered 
with anti-tumor antibodies (Harada et al. 2003; Yan et al. 
2005; Baran et al. 2007; Li et al. 2010; Hong et al. 2003, 
2004). However, divergent results regarding the effect 
of β-glucan on respiratory health have been reported. It 
has been suggested that exposure to microbial products 
or mold can promote the development of asthma (Dou-
wes 2005), while recent data suggest that β-glucans and 
other microbial signals may play a protective role against 
the development of asthma (Heederik and von Mutius 
2012). Furthermore, β-glucan administration has been 
shown to prevent/improve symptoms of allergic rhinitis 
and upper respiratory tract infections (Fuller et al. 2012; 
Yamada et  al. 2007). However, there is minimal data on 
the effect of β-glucan on asthma severity (Sarinho et al. 
2009). In this study, we therefore examined the effect of 
oral administration of particulate β-glucan (WGP) in a 
mouse model of ovalbumin (OVA)-induced asthma. Here 
we demonstrate that oral administration of WGP reduces 
eosinophil influx and the production of Th2 cytokines 
(IL-4, IL-5, IL-13) in the lungs of OVA-challenged mice.
Methods
Animals
C57BL/6 mice were maintained under specific pathogen-
free conditions at the NCI–Frederick, MD. Animal care 
was provided in accordance with the procedures in, “A 
Guide for the Care and Use of Laboratory Animals”. Ethi-
cal approval for the animal experiments detailed in this 
manuscript was received from the Institutional Animal 
Care and Use Committee at the NCI-Frederick.
Oral administration of PBS or WGP
Highly purified particulate β-glucan WGP was isolated 
from the cell wall of Saccharomyces cerevisiae (Biothera, 
Eagen, MN). The β-glucan preparation contained 81  % 
β-1,3/1,6-glucan, 0.5  % mannose, <3.5  % protein and 
<10  % fat. Mice were treated daily with 25–100  μl PBS 
containing 400 μg Wellmune WGP from Biothera or PBS 
alone by oral gavage or alternatively by feeding by pipet 
as needed. Treatment was started 7 days prior to begin-
ning OVA sensitization, and was continued for the dura-
tion of the study.
Sensitization and airway challenge
Allergic airway hypersensitivity to ovalbumin (OVA) was 
induced using grade V chicken egg OVA (Sigma, St. Louis, 
MO). Sensitization was initiated by an intraperitoneal (i.p.) 
injection of 100  μg OVA in 200  μl of 11–13  mg/ml alu-
minum hydroxide colloidal suspension (Alum), followed 
by a second i.p. injection 2 weeks later. Ten days after the 
last sensitization, airway hypersensitivity was induced by 
20-min nebulization sessions challenging with 1  % (w/v) 
OVA in PBS for four consecutive days. Mice were sacri-
ficed, and tissues harvested 24 h after the last nebulization. 
A schematic of the treatment schedule is shown in Fig. 1.
Bronchoalveolar lavage fluid (BALF) collection
Prior to BALF collection, mice were given a ketamine/
xylazine mixture to induce deep anesthesia and analgesia. 
Once sedated, as determined by toe-pinch, the thoracic 
cavity was opened to reveal the lungs and trachea. Using 
a cannula and leur lock syringe, the lungs were expanded 
using 1  mL of PBS and recollected as BALF, for a total 
of 2–3 washes. The mice were euthanized by heart perfu-
sion using 5–10 mL PBS, and the lungs and other tissues 
were collected.
BALF cytospin and differential cell count analysis
Cells from the BAL were collected, and the BALF was 
saved for cytokine analysis. Red blood cell lysis was per-
formed if necessary, cells were washed in PBS, and then 
counted using a hemacytometer. 100  μL containing 
approximately 5 × 104 cells were loaded onto a cytospin 
column and centrifuged onto a microscope slide. Follow-
ing Diffquick cell staining, differential cell counts were 
blindly assessed for each sample, counting at least 500 
cells per slide.
Day:  -7                               0                                                                       14                                                        24  25  26  27  28
Begin daily oral 
administration of
PBS or 400µg WGP
Sensitization
Ovalbumin/Alum i.p.
Sensitization
Ovalbumin/Alum i.p.
Ovalbumin 
(Nebulization challenge)
Harvest
Fig. 1 Schematic for induction of airway inflammation and treatment with WGP. PBS or 400 μg WGP in PBS was orally administered to mice daily via 
oral gavage or pipette feeding. Oral administration of PBS or WGP began 7 days prior to sensitization with ovalbumin (OVA)/Alum and continued 
daily for the duration of the experiment. Mice were sensitized via i.p. injection of 100 μg OVA in 1.8–2.6 mg Alum on Days 0 and 14. Mice were chal-
lenged with OVA (1 % w/v in PBS) for 20 min using a nebulizer on Days 24, 25, 26 and 27. Mice were euthanized 24 h following the last challenge
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BALF assays
BALF was clarified by centrifugation, aliquoted and 
stored at −80 °C for later analysis. Cytokine levels were 
measured in BALF using ELISA kits from eBiosci-
ence (San Diego, CA) and R&D Systems (Minneapolis, 
MN). Myeloperoxidase (MPO) activity in BALF sam-
ples was measured using the Myeloperoxidase activity 
fluorometric assay kit from BioVision (Mountain View, 
CA). Eosinophil peroxidase (EPO) in BALF samples 
was measured using an Eosinophil peroxidase ELISA 
kit (Cusabio Biotech, Wuhan, China). Soluble colla-
gen levels in BALF were measured by adding 200  µL 
of 0.1  % Direct Red 80 in picric acid (Sigma Aldrich, 
St. Louis, MO) to 50  µL of lavage fluid and incubat-
ing for 60 min at 37 °C. The samples were centrifuged 
and the pellet was washed with 100  % ethanol. The 
pellet was resuspended in 200  µl 0.5  M NaOH, incu-
bated for 30 min at 37 °C and the absorbance was read 
at 540 nm.
Lung and spleen cell isolation and flow cytometry
Lung cells were isolated by collagenase and DNase diges-
tion (Sigma Aldrich). Splenocytes were mashed through 
100 µm nylon cell strainers and erythrocytes were lysed 
in ACK buffer. Lung cells were washed with Hank’s 
Balanced Salt Solution (HBSS) and splenocytes were 
washed with PBS. Lung cells and splenocytes were pre-
incubated with the 2.4 G2 antibody to block Fc receptor 
binding, followed by incubation with various cell surface 
Abs: CD3 (17-A2), NK1.1 (PK136), B220 (RA3-6B2), 
F4/80 (BM8), MHCII (M5/114.15.2), (eBioscience, San 
Diego, CA), Siglec F (E50-2440), CD11c (N418), CD11b 
(M1/70), Gr-1 (RB6-8C5) and Ly6G (1A8) (BD Bio-
sciences, San Jose, CA). Cells were fixed with BD Cytofix 
and analysed on BD LSRII.
Blood cell measurement
Blood samples were taken prior to the start of the experi-
ment, and again on the day of harvest. Cell composition 
was measured using the Hemavet 950 automated blood 
cell counter, (Drew Scientific, Waterbury, CT), according 
to the manufacturer’s protocol.
RNA isolation and analysis
A portion of the lung was excised and placed in Trizol 
for RNA isolation. The lung tissue in Trizol was homog-
enized using a mini-beadbeater. RNA was extracted 
using the Trizol protocol and purified using the RNeasy 
Mini Kit (Qiagen, Valencia, CA). cDNA was synthesized 
using Taqman Reverse Transcription Reagents for RT-
PCR (Applied Biosystems). Quantitative RT-PCR was 
performed using ABI Taqman Primer and Probe sets and 
normalization was performed against Hprt1.
Measurement of IgE
Total IgE levels in serum were measured using the IgE 
ELISA from BD Biosciences (San Jose, CA). OVA specific 
IgE was measured using the Legend Max Mouse OVA 
Specific IgE ELISA kit from Biolegend (San Diego, CA).
Lung histology
The lungs were placed in 10  % formalin, embedded in 
paraffin wax blocks and 4  μm sections cut and stained 
for either haematoxylin and eosin (H&E) or periodic 
acid Schiff (PAS) to determine airway inflammation and 
goblet cell metaplasia respectively. All histological sec-
tions were blindly assessed by a pathologist and the total 
number of bronchiole and perivascular aggregates of 
inflammatory cells were counted in each lung. Mucous 
cell metaplasia within the bronchioles was compared to 
normal control tissue and graded as 0 =  no difference, 
1  =  scattered mucous cells, 2  =  aggregates of mucous 
cells, 3 = monolayer layer of mucous cells and 4 = multi-
layered mucous cells.
Statistical analysis
Data are expressed as mean  ±  SEM. Statistical signifi-
cance was determined using Student’s t test or 1-way 
ANOVA followed by Bonferroni’s post-test. Statistical 
significance was set at *p < 0.05, **p < 0.01, ***p < 0.001.
Results
Systemic impact of oral WGP administration
To examine the effect of orally administered WGP on 
allergic airway inflammation, we sensitized and challenged 
WT mice with OVA alongside daily treatments of either 
WGP or PBS, as a vehicle control (Fig. 1). Based on previ-
ous studies where a daily dose of 400 μg of WGP was found 
to be the most effective dose for antitumor responses (Li 
et al. 2010), we administered 400 μg WGP in our study. We 
first examined whether WGP had any systemic effect on 
cellular composition in the blood or other organs as it was 
administered orally to the mice. Overall WGP administra-
tion did not have a major impact on cellular composition 
of the spleen or blood, however subtle effects on some 
cell populations were observed. WGP administration did 
not significantly affect the total number of neutrophils 
(Fig. 2a, c), however it modestly increased the percentage 
of neutrophils in both the spleen and blood (Fig.  2b, e). 
The WBC count was higher in WGP-treated mice, while 
the percentage of WBC was not affected (Fig. 2c, d). The 
WGP-treated mice displayed a small decrease in the per-
centage of lymphocytes, corresponding to the increase 
in the percentage of neutrophils in the blood (Fig. 2c, e). 
Interestingly, other populations including eosinophils and 
monocytes/macrophages in the spleen and the blood were 
unaffected by oral administration of WGP.
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Fig. 2 Systemic impact of oral WGP administration. Cell numbers (a) and percentages (b) in spleens from OVA-challenged mice fed with PBS or 
WGP. Graph displays mean ± SEM from 3 to 4 independent experiments, n = 14–19/group. Cell numbers (c) and percentages (d, e) in blood from 
OVA-challenged mice fed with PBS or WGP. Graph displays mean ± SEM from 2 independent experiments, n = 8–10/group. *p < 0.05 (1-way 
ANOVA, Bonferroni’s post-test)
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WGP reduces total BALF cell numbers and eosinophil 
accumulation
We next examined the effect of orally administered WGP 
on the composition of cell populations present in the 
lungs of mice challenged with OVA. To this end, BALF 
was collected from the lungs and analysis of cells recov-
ered from the BALF revealed that oral administration of 
WGP significantly changed the composition of inflam-
matory cells accumulating due to OVA-induced airway 
hypersensitivity. The total number of cells, total number 
of eosinophils and the percentage of macrophages were 
significantly reduced while the percentage of neutrophils 
was increased in the WGP-treated mice (Fig.  3a, b). As 
MPO activity and EPO levels correspond to the number 
of neutrophils and eosinophils, respectively in a sample, 
we next measured MPO and EPO levels in the BALF. 
While the percentage of neutrophils was increased in 
WGP-treated mice, MPO activity in the BALF was simi-
lar between PBS and WGP-treated mice (Fig. 3c). This is 
likely due to the similar total number of neutrophils in 
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Fig. 3 Effect of oral administration of WGP on BALF cells in OVA-challenged mice. Cell numbers (a) and percentages (b) in BALFs from OVA-
challenged mice fed with PBS or WGP. Graphs display mean ± SEM from 4 independent experiments, n = 19/group. c MPO Activity in BALF. Graph 
displays mean ± SEM from 5 independent experiments (n = 21–22/group). d EPO levels in BALF. Graph displays mean ± SEM from 3 independent 
experiments (n = 15/group). a–d *p < 0.05 (Student’s t test). e Graphs display correlation between number of eosinophils and number of neutro-
phils or macrophages present in BALF
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the BALF from PBS and WGP-treated mice. EPO lev-
els were reduced in WGP-treated mice (Fig.  3d), which 
is consistent with the reduced eosinophil numbers in 
the BALF from these mice. Correlation analysis was 
then performed to determine whether there was a link 
between the number of eosinophils and the number of 
neutrophils and/or macrophages in the BALF. While 
there was no correlation between the number of eosino-
phils and neutrophils, a positive correlation between the 
number of eosinophils and macrophages was observed 
(Fig.  3e). These data indicate that oral administration 
of WGP significantly inhibits the local recruitment of 
inflammatory cells, in particular eosinophils and to a 
lesser extent macrophages, to the lungs in this model of 
allergic inflammation while it promotes a subtle systemic 
increase in neutrophils.
WGP modulates lung cellular composition
As we observed differences in BALF cellular composi-
tion, we examined the effect of WGP on lung cellular 
composition. Similar to our findings in BALF, infiltration 
of both eosinophils and macrophages were significantly 
reduced in both percentage (Fig. 4a; Additional file 1: Fig. 
S1) and total cell number (Fig. 4b). While the percentage 
of neutrophils was increased in the lungs of WGP-treated 
mice compared to PBS-treated mice (Fig. 4b; Additional 
file 1: Fig. S1), no significant difference was observed in 
the total number of infiltrating neutrophils (Fig. 4a), nor 
were there any alterations in lymphocyte infiltration 
(Fig. 4a, b). Taken together these data indicate that WGP 
significantly inhibits the recruitment of eosinophils and 
macrophages to the lungs of these mice while it promotes 
a modest increase in neutrophil recruitment.
WGP does not affect OVA‑induced histopathological 
changes in the lung
To determine the effect of WGP on OVA-induced his-
topathological changes in the lung, lung sections were 
stained with H&E and scored. H&E sections from a rep-
resentative mouse treated with PBS (Fig.  5a, b) demon-
strate the expected prominent epithelial infolding and 
lumen reduction related to mucous cell metaplasia asso-
ciated with OVA-induced inflammatory response. The 
surrounding tissue shows peribronchiole and perivascu-
lar inflammatory infiltrates comprising lymphocytes with 
scattered eosinophils. Similar features were seen in mice 
treated with WGP (Fig. 5d, e) although in this section the 
changes within the bronchiole are subtle and the lympho-
cytic infiltrate denser. Variable changes were seen in dif-
ferent areas of the lung with a mixed inflammatory cell 
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Fig. 4 Effect of oral administration of WGP on lung cellular composition in OVA-challenged mice. Cell numbers (a) and percentages (b) in lungs 
from OVA-challenged mice fed with PBS or WGP. Graphs display mean ± SEM from 3 independent experiments, n = 13–14/group. a–d *p < 0.05, 
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Fig. 5 Effect of oral administration of WGP on lung histology and soluble collagen. a–f Representative sections from both treatment groups 
demonstrate the varied morphological changes seen within the lung. H&E sections from a representative mouse treated with PBS (a, b) and a 
representative mouse treated with WGP (d, e). PAS stains from different areas reveal mucous cell metaplasia in each group (c, f). g, h Graphs display 
mean ± SEM. Inflammatory Focus Score (g) and Mucus Cell Score (h). Graphs are the cumulative result of 2 independent experiments (n = 10). i 
Graph displays mean ± SEM of soluble collagen levels in BALF. Graph is the cumulative result of 5 independent experiments (n = 22–23)
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infiltrate predominantly observed in peribronchial and 
perivascular areas in OVA-challenged mice; however, 
WGP had no effect on these changes (Fig. 5a, b, d, e, g). 
Similar features were seen in bronchioles of both PBS and 
WGP-treated mice with folded epithelium and narrow-
ing of lumens and no differences in goblet cell metapla-
sia or mucous production (Fig. 5c, f, h). As lung fibrosis/
airway remodeling is characterized by enhanced collagen 
deposition (Yamauchi et  al. 2008) we assayed the BALF 
for soluble collagen. Similar to the histological findings, 
soluble collagen levels in the lung were similar between 
PBS and WGP-treated mice (Fig. 5i), demonstrating that 
some aspects of the airway hyperesponsiveness model 
are unaffected by WGP treatment.
WGP reduces Th2 cytokine levels in the lung
Th2 cells secreting IL-4, IL-5 and IL-13 are important 
for eosinophil recruitment and survival and for IgE pro-
duction (Monick et  al. 2001). To further investigate the 
effect of WGP on allergic inflammation, cytokine levels 
(Th1, Th2 and Th17) in the lungs of PBS and OVA-chal-
lenged mice were measured. Consistent with previously 
published data from this model, OVA challenged mice 
displayed increased levels of these cytokines in the lungs 
compared to PBS challenged mice (data not shown). 
Interestingly, the levels of Il4 and Il5 mRNA, which are 
important for eosinophil recruitment, along with Il13, 
were reduced in the lungs of WGP-treated OVA-chal-
lenged mice (Fig.  6a), while Th1 (Ifng) and Th17 (Il17) 
cytokine mRNA levels remained similar between PBS 
and WGP-treated OVA-challenged mice. In addition 
there was no change in the Treg population, as mRNA 
levels of Foxp3, the transcription factor for Tregs, were 
similar between PBS and WGP-treated mice (Fig.  6a). 
Consistent with the mRNA data, IL-4, IL-5 and IL-13 
protein levels were significantly reduced in WGP-treated 
mice while IFN-γ and IL-17 levels were mostly not 
detected (Fig.  6b and data not shown). As IgE produc-
tion is an important aspect of the OVA-challenge asthma 
model, we next examined IgE production in the serum 
of these mice. Total IgE levels and OVA-specific IgE lev-
els (Fig. 6c) were similar between PBS and WGP-treated 
mice. Together, these data demonstrate reduced Th2 
cytokine production in WGP-treated mice compared to 
PBS-treated mice while Th1 and Th17 cytokine levels are 
similar between the two groups.
Discussion
Several natural products are advertised as immunothera-
peutics and many claims are made about their effects 
on a wide range of diseases including asthma. Here we 
tested the effect of Wellmune WGP β-1,3/1,6-glucan dur-
ing a mouse model of OVA-induced asthma. We dem-
onstrated that daily oral administration of WGP reduces 
eosinophil influx into the lungs and the production of 
Th2 cytokines (IL-4, IL-5, IL-13) compared to control 
mice. Serum IgE levels and OVA-specific IgE levels were 
unaffected by administration of WGP. Together these 
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data indicate that WGP administration would not, in and 
of itself, be sufficient as a single treatment for asthma, 
however as it targets the critical initiator step in asthma 
immune responses (or similar) it may prove useful as a 
combination therapy.
Asthma is a heterogeneous disease and patients pre-
sent with various distinct clinical phenotypes. Different 
mouse models are being developed to model the differ-
ent phenotypes found in asthma patients (Lloyd and 
Hessel 2010; Nials and Uddin 2008; Lloyd 2007). The 
OVA-induced airway hypersensitivity model of asthma 
used here results in eosinophilic inflammation in the 
lung, pulmonary production of Th2 cytokines (IL-4, IL-5 
and IL-13) and serum IgE production (Lloyd and Hessel 
2010; Lloyd 2007). The role of Th2 cells in patients with 
asthma is well established and T cell activation has been 
related to asthma severity in some studies (Walker et al. 
1991; Robinson et  al. 1993). IL-4, IL-5 and IL-13 have 
been shown to have roles in IgE production, eosino-
phil survival, AHR development and tissue remodeling 
(Finkelman et  al. 2010). Here we observed a significant 
reduction in production of Th2 cytokines and eosinophil 
influx with WGP administration, although this does not 
reach a threshold to see histological differences. Addi-
tionally, IgE production and soluble collagen levels were 
unaffected by the administration of WGP. Therefore, 
while other factors in addition to Th2 cells/cytokines are 
involved in the pathogenesis of asthma (Lloyd and Hes-
sel 2010), it appears that WGP is specific in targeting the 
production of IL-4, IL-5, IL-13 and resulting eosinophilia 
in this model. This targeted effect is important as local 
production of these cytokines is associated with AHR 
development and downstream complications. While our 
results indicate no impact on collagen-deposition or lung 
pathology, these studies may only represent an acute 
effect. It is possible that with long-term WGP-adminis-
tration after asthma is established or in combination with 
other therapies, the continued decrease in Th2 responses 
could protect against damaging inflammation and fibro-
sis in the lung.
β-Glucan has immunomodulating properties and it has 
been shown to exert beneficial therapeutic effects against 
various diseases including allergic diseases. One study 
demonstrated that administration of WGP to ragweed 
allergy sufferers reduced allergy symptoms however sim-
ilar to our findings it had no effect on serum IgE levels 
(Talbott et al. 2013). Another study showed that β-glucan 
administration to subjects with seasonal allergic rhinitis 
resulted in reduced IL-4 and IL-5 levels (Kirmaz et  al. 
2005). Our data demonstrating reduced IL-4 and IL-5 
levels in WGP-treated mice in an OVA-induced asthma 
model is in agreement with these findings. In addition a 
study demonstrated a reduction in asthmatic symptoms 
following β-glucan administration and increased IL-10 
levels (Sarinho et al. 2009).
Conclusions
Daily oral administration of WGP (400  µg) significantly 
reduced pulmonary eosinophil influx and production 
of Th2 cytokines (IL-4, IL-5, IL-13), however serum IgE 
levels were unaffected by WGP treatment in an OVA-
induced asthma model. Our findings suggest that WGP 
could be used to target some aspects of asthma (Th2 
cytokines and eosinophilia). While WGP alone would not 
be sufficient to treat asthma, it could be used in combi-
nation with other therapies that target different aspects 
of the disease such as IgE levels. As WGP is an oral 
supplement, it could be considerably more cost effec-
tive and may have fewer side effects than immunothera-
pies. In addition, as IL-4, IL-5 and IL-13 are all reduced 
in response to WGP, the broader effects of WGP could 
be more beneficial than immunotherapies that target 
one specific cytokine such as IL-4 or IL-5. Further stud-
ies would need to be conducted to determine the effect 
of WGP in combination with other therapies for specific 
subsets of asthma patients.
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